| 25A472 |
Takeda Pharmaceutical Company Limited, a Japanese Corporation, et al. v. Painters & Allied Trades District Council 82 Health Care Fund, third-party healthcare payor
fund, et al. |
Ninth Circuit |
2025-10-24 |
Application |
causation class-certification individualized-damages injury-requirement rico-claim third-party-payor |
Whether a class action under Rule 23(b)(3) can be certified for a RICO claim when individual plaintiffs cannot demonstrate uniform injury or causation… |
| 25-440 |
Thomas Anderson, et al. v. United Airlines, Inc., et al. |
Seventh Circuit |
2025-10-10 |
Denied |
None |
Section 564 of the Food , Drug, and Cosmetics Act
("FDCA") provides that the Food and Drug Administration 's ("FDA") standard process for approving
… |
| 25-257 |
Wells Pharma of Houston, L.L.C. v. Zyla Life Sciences, L.L.C. |
Fifth Circuit |
2025-09-04 |
Pending |
consumer-protection drug-marketing fdca-preemption outsourcing-facilities premarket-approval state-law-claims |
Whether the FDCA preempts private state-law unfair competition and consumer protection claims premised on the marketing of compounded drugs without pr… |
| 25-141 |
Arnold G. Phillips v. Cecilia Abundis, et al. |
Seventh Circuit |
2025-08-06 |
Denied |
administrative-hearing atomic-energy-act due-process medical-license nuclear-medicine settlement-agreement |
Whether the United States District Court for the Northern District of Illinois improperly suspended a medical license without notice or hearing in vio… |
| 24-1187 |
Vanda Pharmaceuticals, Inc. v. Food and Drug Administration, et al. |
District of Columbia |
2025-05-21 |
Denied |
administrative-law agency-discretion drug-approval fda-regulation medical-innovation statutory-interpretation |
Whether FDA has acted contrary to its statutory mandate by substituting an evaluation of a drug development program's potential for assessing a new dr… |
| 24A871 |
Vanda Pharmaceuticals, Inc. v. Food and Drug Administration, et al. |
District of Columbia |
2025-03-12 |
Presumed Complete |
None |
|
| 24A724 |
Johnny Copper, LLC v. Food and Drug Administration, et al. |
Eleventh Circuit |
2025-01-23 |
Presumed Complete |
administrative-law agency-overreach fda-regulation procedural-due-process regulatory-burden statutory-interpretation |
Whether the FDA exceeded its statutory authority in issuing a regulatory order that imposes substantial burdens on a regulated entity without providin… |
| 24-474 |
Food and Drug Administration v. SWT Global Supply, Inc., et al. |
Fifth Circuit |
2024-10-29 |
GVR |
administrative-law arbitrary-and-capricious-standard e-cigarette-products fda-authorization public-health tobacco-control-act |
Whether the court of appeals erred in setting aside FDA's denial orders as arbitrary and capricious |
| 24-239 |
Kenneth Chloe v. George Washington University |
District of Columbia |
2024-09-03 |
Denied |
administrative-procedure chevron-doctrine constitutional-rights due-process judicial-review separation-of-powers |
Whether the United States District Court and Court of Appeals violated constitutional rights through administrative rulemaking and potential breach of… |
| 24-189 |
R.J. Reynolds Tobacco Company, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2024-08-21 |
Denied |
commercial-speech first-amendment government-mandated-warnings graphic-warnings tobacco-regulation zauderer-standard |
Whether provocative and misleading government-mandated graphic warnings on cigarette packaging are 'purely factual and uncontroversial' under Zauderer… |
| 23-1187 |
Food and Drug Administration, et al. v. R.J. Reynolds Vapor Co., et al. |
Fifth Circuit |
2024-05-02 |
Judgment Issued |
administrative-law circuit-court civil-procedure fda fda-authorization federal-courts judicial-review product-distribution standing statutory-interpretation tobacco-regulation |
Whether a manufacturer may file a petition for review in a circuit (other than the D.C. Circuit) where it neither resides nor has its principal place … |
| 23-1161 |
Children’s Health Defense, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2024-04-26 |
Denied |
agency-action article-iii case-or-controversy constitutional-standing injury-in-fact resource-diversion standing vaccine-safety |
Whether a Constitutionally cognizable case or controversy exists under Article III |
| 23-1125 |
Logic Technology Development LLC v. Food and Drug Administration |
Third Circuit |
2024-04-17 |
Denied |
administrative-law agency-action arbitrary-and-capricious electronic-nicotine-delivery-system electronic-nicotine-delivery-systems fda-regulation menthol-flavoring premarket-tobacco-application premarket-tobacco-product-application retroactive-rulemaking retroactive-standard |
Whether the FDA's creation of a new, heightened standard for evaluating already-pending PMTAs for certain ENDS products was arbitrary and capricious |
| 23-1038 |
Food and Drug Administration v. Wages and White Lion Investments, L.L.C., dba Triton Distribution, et al. |
Fifth Circuit |
2024-03-19 |
Judgment Issued |
administrative-law agency-decision agency-deference arbitrary-and-capricious e-cigarettes fda-regulation interstate-commerce public-health tobacco-control tobacco-regulation |
Whether the court of appeals erred in setting aside FDA's denial orders as arbitrary and capricious |
| 23A779 |
Logic Technology Development LLC v. Food and Drug Administration |
Third Circuit |
2024-02-26 |
Presumed Complete |
administrative-law agency-rulemaking arbitrary-capricious electronic-nicotine fda-regulation marketing-application |
Whether the FDA improperly adopted a new and heightened evidentiary burden for marketing applications for electronic nicotine delivery systems (ENDS) … |
| 23-871 |
Lotus Vaping Technologies, LLC v. Food and Drug Administration |
Ninth Circuit |
2024-02-13 |
Denied |
administrative-procedure-act arbitrary-and-capricious circuit-split comparative-efficacy electronic-nicotine-delivery-systems fair-warning flavored-products food-and-drug-administration marketing-applications |
Whether FDA's denial of Petitioner's marketing applications for flavored ENDS was arbitrary and capricious |
| 23-799 |
Magellan Technology, Inc. v. Food and Drug Administration |
Second Circuit |
2024-01-24 |
Denied |
administrative-procedure-act agency-rulemaking arbitrary-and-capricious circuit-split comparative-efficacy electronic-nicotine-delivery-systems ends-products fda-regulation marketing-authorization reliance-interests youth-access |
Whether FDA's denial of Petitioner's marketing applications for flavored ENDS was arbitrary and capricious |
| 23-788 |
Hope Medical Enterprises, Inc., dba Hope Pharmaceuticals v. Fagron Compounding Services, LLC, et al. |
Ninth Circuit |
2024-01-22 |
Denied |
circuit-split drug-regulation federal-law federal-preemption food-and-drug-administration preemption state-law state-rights statutory-interpretation |
Whether the FDCA preempts state laws prohibiting the in-state sale of unapproved drugs whose sale is also prohibited as a matter of federal law by the… |
| 23A530 |
Hope Medical Enterprises, Inc. v. Fagron Compounding Services, LLC, et al. |
Ninth Circuit |
2023-12-12 |
Presumed Complete |
drug-approval enforcement fdca preemption private-litigation state-law |
Whether the Food, Drug, and Cosmetic Act's enforcement provision preempts state-law claims that mirror federal drug approval requirements |
| 23A507 |
Lotus Vaping Technologies, LLC v. Food and Drug Administration |
Ninth Circuit |
2023-12-05 |
Presumed Complete |
administrative-procedure agency-discretion evidentiary-standards fair-notice marketing-denial regulatory-review |
Whether the Administrative Procedure Act permits a federal agency to change its evidentiary standards for regulatory approval without providing fair n… |
| 23A421 |
Magellan Technology, Inc. v. Food and Drug Administration |
Second Circuit |
2023-11-15 |
Presumed Complete |
administrative-law arbitrary-and-capricious circuit-split evidentiary-standards fair-notice fda-regulation |
Whether the FDA's marketing denial order for electronic nicotine delivery system (ENDS) products was arbitrary and capricious by changing evidentiary … |
| 23A344 |
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al. |
Federal Circuit |
2023-10-17 |
Presumed Complete |
KSR-standard obviousness patent-law pharmaceutical-patents predictable-result prior-art |
Whether the Federal Circuit's obviousness analysis complies with the Supreme Court's standard in KSR International Co. v. Teleflex Inc. by requiring t… |
| 23-395 |
Alliance for Hippocratic Medicine, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2023-10-16 |
Denied |
abortion abortion-medication administrative-procedure-act drug-regulation fda fda-approval generic-drugs medical-safety mifepristone subpart-h |
Whether Cross-Petitioners' challenge to FDA's 2000 mifepristone approval is timely |
| 23-236 |
Danco Laboratories, L.L.C. v. Alliance for Hippocratic Medicine, et al. |
Fifth Circuit |
2023-09-12 |
Judgment Issued |
administrative-procedure-act administrative-record agency-deference article-iii-standing circuit-split fda-drug-approval judicial-review national-scope preliminary-injunction |
Whether an association can demonstrate Article III standing to enjoin a government action |
| 23-235 |
Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al. |
Fifth Circuit |
2023-09-12 |
Judgment Issued |
abortion abortion-medication administrative-law agency-action article-iii-standing civil-procedure fda fda-regulations mifepristone preliminary-relief standing |
Whether respondents have Article III standing to challenge FDA's 2016 and 2021 actions |
| 23A181 |
Joseph R. Biden, Jr., President of the United States, et al. v. Greg Abbott, Governor of Texas, et al. |
Fifth Circuit |
2023-08-28 |
Presumed Complete |
constitutional-separation-of-powers covid-19-vaccination federal-authority militia-clauses national-guard state-militia-capacity |
Whether the Militia Clauses of the Constitution, Article I, Sections 8, Clauses 15 and 16, prohibit the federal government from imposing a COVID-19 va… |
| 22-1180 |
Shire U.S., Inc., et al. v. Mark Blackburn |
Eleventh Circuit |
2023-06-07 |
Denied |
drug-labeling fda-preapproval FDA-regulations federal-preemption pliva-v-mensing preemption prescription-drugs state-law-claim state-law-claims unilateral-change unilateral-label-changes |
Whether a state-law claim is preempted if it places a duty on a drug manufacturer to unilaterally change FDA-approved language that appears in the Hig… |
| 22-1121 |
Kamaladoss Selvam v. United States, et al. |
Second Circuit |
2023-05-17 |
Denied |
administrative-law administrative-warrant civil-procedure drug-enforcement fda-jurisdiction federal-agencies law-enforcement search-and-seizure search-warrant statutory-interpretation subpoena-power |
Whether the FDA has jurisdiction to enforce the Drug Abuse Prevention and Control Act |
| 22-1112 |
Avail Vapor, LLC, et al. v. Food and Drug Administration |
Fourth Circuit |
2023-05-15 |
Denied |
administrative-law administrative-procedure-act arbitrary-and-capricious evidence-standard evidentiary-standard fda fda-regulation marketing-authorization premarket-applications tobacco-product-regulation tobacco-products |
Whether FDA's marketing denial order was arbitrary and capricious |
| 22A902 |
Food and Drug Administration, et al. v. Alliance For Hippocratic Medicine, et al. |
Fifth Circuit |
2023-04-14 |
Presumed Complete |
None |
|
| 22A777 |
Avail Vapor, LLC, et al. v. Food and Drug Administration |
Fourth Circuit |
2023-03-03 |
Presumed Complete |
None |
|
| 22-757 |
Jonathan Roberts, et al. v. James V. McDonald, Commissioner, New York State Department of Health, et al. |
Second Circuit |
2023-02-10 |
Denied |
civil-rights defendant-conduct due-process emergency-approval equal-protection injury-in-fact legal-standing predictable-events racial-discrimination standing |
Whether plaintiffs' injury is imminent where it flows from a predictable course of events that results from the defendant's conduct |
| 22-708 |
Gripum, LLC v. Food and Drug Administration |
Seventh Circuit |
2023-01-30 |
Denied |
administrative-agencies administrative-law administrative-procedure-act agency-deference conflicts-of-interest evidentiary-requirements fda-guidance judicial-deference judicial-review regulatory-conflict tobacco-control-act |
What level of judicial deference is afforded to administrative agencies with conflicts of interest? |
| 22-584 |
Children’s Health Defense, et al. v. Food and Drug Administration, et al. |
Sixth Circuit |
2022-12-23 |
Denied |
agency-action article-iii case-or-controversy constitutional-standing injury resource-diversion risk-of-injury standing third-party third-party-injury |
Whether a Constitutionally cognizable case or controversy exists under Article III |
| 22A482 |
Gripum, LLC v. Food and Drug Administration |
Seventh Circuit |
2022-12-01 |
Presumed Complete |
None |
|
| 21-1342 |
Jacobus Pharmaceutical Company, Inc. v. Catalyst Pharmaceuticals, Inc., et al. |
Eleventh Circuit |
2022-04-11 |
Dismissed |
administrative-law circuit-split drug-exclusivity fda fda-regulation lambert-eaton-myasthenic-syndrome orphan-drug-act rare-disease statutory-interpretation |
Does the Orphan Drug Act unambiguously foreclose FDA's interpretation that the scope of orphan-drug exclusivity is tied to a drug's approved use? |
| 21A176 |
Breeze Smoke, LLC v. Food and Drug Administration |
Sixth Circuit |
2021-11-23 |
Presumed Complete |
None |
|
| 20-1203 |
Moose Jooce, et al. v. Food and Drug Administration, et al. |
District of Columbia |
2021-03-03 |
Denied |
administrative-procedure-act agency agency-law appointments-clause due-process government-action ratification ratification-doctrine rulemaking-authority standing |
Whether a government official has the power to validate the unauthorized actions of other officials is presumptively determined by the law of agency, … |
| 20-1069 |
Janssen Pharmaceuticals, Inc., et al. v. A. Y., et al. |
Pennsylvania |
2021-02-05 |
Denied |
civil-liability drug-labeling fda-regulation federal-preemption impossibility-preemption off-label-use preemption state-tort-law |
Whether federal law preempts state-law claims that a manufacturer failed to provide adequate warnings relating to the off-label use of their products,… |
| 20-850 |
Big Time Vapes, Incorporated, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2020-12-28 |
Denied |
administrative-discretion administrative-law constitutional-limits executive-authority executive-power legislative-authority legislative-delegation non-delegation-doctrine separation-of-powers tobacco-control-act tobacco-product-regulation |
Whether Petitioners have stated a claim that § 387a(b) grants excessive policymaking discretion to the executive branch to determine which tobacco pro… |
| 20-779 |
Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corporation |
Federal Circuit |
2020-12-08 |
Denied |
administrative-proceeding article-iii-standing article-three-standing fda-approval inter-partes-review joint-venture leahy-smith-america-invents-act patent-challenge patent-validity pharmaceutical-industry pharmaceutical-patent |
Did the Federal Circuit categorically and erroneously preclude redress for injured members of joint ventures in the pharmaceutical industry by only re… |
| 20-451 |
Jane Doe, Individually and as Parent and Guardian of Baby Doe, et al. v. Merck & Co., Inc., et al. |
Second Circuit |
2020-10-08 |
Denied |
citizens-action civil-rights due-process fda-licensing fda-regulation primary-jurisdiction standing thimerosal vaccine-act vaccine-injury vaccine-mandate |
Whether courts should extend the precedent of Jacobson v. Massachusetts to require that a mandated vaccine be necessary, harm-avoidant, proportional a… |
| 20-295 |
Hi-Tech Pharmaceuticals, Inc., et al. v. Food and Drug Administration, et al. |
Eleventh Circuit |
2020-09-08 |
Denied |
botanical-ingredients constituent-definition dietary-supplements dmaa DSHEA FDA-approval federal-food-drug-and-cosmetic-act geranium-plants prior-history-of-use trace-quantities |
Whether a substance that naturally occurs in a plant is a 'constituent' of an 'herb or other botanical' under the Dietary Supplement Health and Educat… |
| 20A34 |
Food and Drug Administration, et al. v. American College of Obstetricians and Gynecologists, et al. |
Fourth Circuit |
2020-08-26 |
Presumed Complete |
None |
|
| 19-1038 |
Department of Health and Human Services, et al. v. California, et al. |
Ninth Circuit |
2020-02-19 |
GVR |
administrative-law affordable-care-act conscience-exemption contraceptive-coverage contraceptive-mandate health-insurance preventive-services religious-freedom-restoration-act |
Whether the agencies had statutory authority under the ACA and the Religious Freedom Restoration Act of 1993 to expand the conscience exemption to the… |
| 19-454 |
Donald J. Trump, President of the United States, et al. v. Pennsylvania, et al. |
Third Circuit |
2019-10-07 |
Judgment Issued |
administrative-procedure-act affordable-care-act agency-rulemaking conscience-exemption contraceptive-coverage contraceptive-mandate healthcare-mandate nationwide-injunction religious-freedom-restoration-act standing statutory-authority |
Whether the agencies had statutory authority to expand the conscience exemption to the contraceptive-coverage mandate |
| 18-182 |
AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc., et al. |
Federal Circuit |
2018-08-09 |
Denied |
actual-controversy article-iii declaratory-judgment drug-exclusivity fda-approval generic-drugs patent-invalidity pharmaceutical pharmaceutical-patents standing |
Whether the 'actual controversy' requirement of the Declaratory Judgment Act requires a party seeking to introduce a generic drug product to file an a… |
| 23A301 |
Danco Laboratories, L.L.C. v. Alliance for Hippocratic Medicine, et al. |
Fifth Circuit |
|
Presumed Complete |
None |
Question not identified. |
| 23A712 |
Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al. |
Fifth Circuit |
|
Presumed Complete |
administrative-law chemical-abortion drug-safety fda-regulation medical-procedure reproductive-rights |
Whether the FDA's regulatory framework for chemical abortion drugs satisfies the requirements of the Food, Drug, and Cosmetic Act and does not pose un… |
| 23A300 |
Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al. |
Fifth Circuit |
|
Presumed Complete |
None |
Question not identified. |